Rhythm Pharmaceuticals (RYTM) Gains from Investment Securities: 2016-2025
Historic Gains from Investment Securities for Rhythm Pharmaceuticals (RYTM) over the last 6 years, with Sep 2025 value amounting to $5.2 million.
- Rhythm Pharmaceuticals' Gains from Investment Securities rose 677.31% to $5.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $27.6 million, marking a year-over-year increase of 975.93%. This contributed to the annual value of $6.6 million for FY2024, which is 0.92% up from last year.
- Per Rhythm Pharmaceuticals' latest filing, its Gains from Investment Securities stood at $5.2 million for Q3 2025, which was up 196.64% from -$5.4 million recorded in Q2 2025.
- In the past 5 years, Rhythm Pharmaceuticals' Gains from Investment Securities registered a high of $27.9 million during Q4 2024, and its lowest value of -$5.4 million during Q2 2025.
- Its 3-year average for Gains from Investment Securities is $2.1 million, with a median of -$537,000 in 2023.
- Over the last 5 years, Rhythm Pharmaceuticals' Gains from Investment Securities had its largest YoY gain of 697,450.00% in 2024, and its largest YoY loss of 1,307.07% in 2024.
- Over the past 5 years, Rhythm Pharmaceuticals' Gains from Investment Securities (Quarterly) stood at $1.3 million in 2021, then plummeted by 100.08% to -$1,000 in 2022, then surged by 500.00% to $4,000 in 2023, then spiked by 697,450.00% to $27.9 million in 2024, then skyrocketed by 677.31% to $5.2 million in 2025.
- Its last three reported values are $5.2 million in Q3 2025, -$5.4 million for Q2 2025, and -$102,000 during Q1 2025.